| Symbol | JBIO |
|---|---|
| Name | JADE BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 221 CRESCENT ST.,BUILDING 23,SUITE 105, WALTHAM, Massachusetts, 02453, United States |
| Telephone | +1 781 312-3013 |
| Fax | — |
| — | |
| Website | https://www.aerovatetx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001798749 |
| Description | Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the cytokine APRIL for immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jades pipeline also includes two undisclosed antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Jade Biosciences, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001231919-26-000932 <b>Size:</b> 18 KB
Read moreNew Form SCHEDULE 13G/A - Jade Biosciences, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-096751 <b>Size:</b> 10 KB
Read more(10% Negative) JADE BIOSCIENCES, INC. (JBIO) Reports Q3 2026 Financial Results
Read moreJade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreNew Form SCHEDULE 13G - Jade Biosciences, Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001104659-26-084623 <b>Size:</b> 16 KB
Read moreEisner Mark 🟢 acquired 47.7K shares (1 derivative) of Jade Biosciences, Inc. (JBIO) at $21.81 ($1.0M) Transaction Date: Jun 25, 2026 | Filing ID: 286434
Read moreNew Form 3 - Jade Biosciences, Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001193125-26-286421 <b>Size:</b> 12 KB
Read more(10% Negative) JADE BIOSCIENCES, INC. (JBIO) Announces Delay in Development Trials for Immunology Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreJade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Read moreCAIN CHRISTOPHER W. 🟢 acquired 34.8K shares (1 derivative) of Jade Biosciences, Inc. (JBIO) at $15.22 Transaction Date: Jun 09, 2026 | Filing ID: 267764
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07533955 | A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis | Phase1 | Rhematoid Arthritis | Recruiting | 2026-05-19 | 2028-10-01 | ClinicalTrials.gov |
| NCT07541287 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy | Phase2 | IgA Nephropathy | Recruiting | 2026-05-19 | 2029-04-01 | ClinicalTrials.gov |
| NCT07525947 | A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Partici… | Phase1 | Healthy Volunteers (HV) | Recruiting | 2026-05-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT07059312 | A Phase 1 Study of JADE101 in Healthy Participants | Phase1 | Healthy Volunteers | Active_Not_Recruiting | 2025-08-17 | 2026-10-01 | ClinicalTrials.gov |
| NCT03452280 | Validation of the JADE wRAP™, a Novel Blood Pressure Measurement Device, Using … | — | Blood Pressure | Unknown | 2017-12-18 | 2021-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | RECRUITING | NCT07541287 |
| JADE101 | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07525947 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | RECRUITING | NCT07533955 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | RECRUITING | NCT07541287 |
| JADE101 | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07525947 |
| JADE101 | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07525947 |
| JADE101 | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07525947 |
| JADE101 | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07525947 |
| JADE101 | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07525947 |
| JADE101 | Other | Phase PHASE1 | Healthy Volunteers (HV) | RECRUITING | NCT07525947 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07059312 |
| JADE101 | Other | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07059312 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT07541287 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT07541287 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT07541287 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT07541287 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT07541287 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT07541287 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT07541287 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE101 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT07541287 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| Placebo | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| JADE201 | Other | Phase PHASE1 | Rhematoid Arthritis | NOT_YET_RECRUITING | NCT07533955 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07059312 |
| JADE101 | DRUG | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07059312 |